United Therapeutics net income grows 11 percent in 2Q
SILVER SPRING, Md. -- United Therapeutics Corp.’s net income grew about 11 percent in the second quarter to about $79.9 million, the company announced Thursday.
Total revenues were up 24 percent to about $280.6 million. The company saw increased sales of each of its three treatments for pulmonary arterial hypertension, a disease characterized by increased pressure in the pulmonary artery.
That increased pressure strains the right side of the heart as it pumps blood to the lungs, according to information from the company, which can lead to right heart failure and death.
United Therapeutics has research and development and other operations in the Research Triangle Park. The company is planning to build additional facilities in the park, beginning construction this year on research and development and office space for a regenerative medicine and xenotransplantation program.
Biogen Idec reports 27 percent growth in 2Q net income
WESTON, Mass. -- Biogen Idec, a Massachusetts-based drug company that has operations in the Research Triangle Park, reported Thursday that its net income was up 27 percent to $491 million in the second quarter.
The company’s total revenues were $1.7 billion in the quarter, up 21 percent. The company saw a 2 percent revenue increase for the multiple sclerosis drug Avonex and a 38 percent increase for Tysabri, which is also a treatment for multiple sclerosis. The company said it saw a bump in revenues for Tysabri after acquiring all of the rights in the therapy from Elan.